Glycated haemoglobin (HbA1c) is a routinely used marker for long-term glycaemic control. Apart from functioning as an indicator for the mean blood glucose level, HbA1c also predicts the risk for the development of diabetic complications in diabetes patients. Many studies have proposed HbA1c to be used as a biomarker of both glycaemic control and dyslipidemia in type 2 diabetes mellitus. Hence based on above reported findings the present study was planned for Assessment of Changes. Total 40 cases were enrolled in the present study. The present study was planned in Department of General medicine, ICARE Institute of Medical Sciences and Research & Dr. Bidhan Chandra Roy Hospital, Haldia, West Bengal, India. The study was conducted from the duration one year.The cases were divided in two study groups as Diabetic patients and normal patients of 20 cases each. The data generated from the present study concludes that there is significant correlation was observed between HbA1c and various parameters of lipid profile, and there is no standardized protocol to compare the results of various other studies hence more structured and long term studies on larger no of patients are needed to validate HbA1c as a marker of dyslipidemia. Diabetic dyslipidemia or atherogenic dyslipidemia is characterized by low HDL, high TG and high small dense LDL. Early screening of diabetic patients for dyslipidemia and early intervention is required to minimize the risk of future cardiovascular mortality.

http://impactfactor.org/PDF/IJTPR/12/IJTPR,Vol12,Issue12,Article3.pdf